Zell | $589,875 | (Apr 14, 2026)
Qoro | $750,000 | (Apr 14, 2026)
Remission Medical | Undisclosed Amount | (Apr 14, 2026)
Certified by Founder
Lodge
ErVimmune
start up
- 21/01/2026
- Series A
- $19,917,795
Targeting shared unconventional tumor antigens in cancer immunotherapy
- Industry Biotechnology Research
- Website https://ervimmune.com/
- LinkedIn https://www.linkedin.com/company/ervimmune/
Related People
Stéphane DEPILFounder
France -
Onco-hematologist at Centre Léon Bérard and leader of the team "Antigen presentation, T cell and Cancer" at Cancer Research Center of Lyon. Over 20 years of experience in oncology research and drug development both in academia and pharma/biotech companies as former SVP R&D and CMO at Cellectis, CEO at Netris Pharma and Head of OncologyR&D at Servier.Founder and board member of ErVimmune, a biotech company developing cancer vaccines and T cell therapies targeting non-conventional tumor epitopes.
Pixel Photonics | $5,880,875 | (Apr 14, 2026)
Critical Loop | $26,000,000 | (Apr 14, 2026)
AIRMO | $5,880,175 | (Apr 14, 2026)
Primepoint | $10,000,000 | (Apr 14, 2026)
Slate Auto | $650,000,000 | (Apr 14, 2026)
Quartzy | $23,000,000 | (Apr 14, 2026)
Citra Space Corporation | $15,000,000 | (Apr 14, 2026)
Flashpass | $4,250,000 | (Apr 14, 2026)